219 related articles for article (PubMed ID: 23103500)
21. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
22. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
23. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
24. Flavonoids and hERG channels: Friends or foes?
Saponara S; Fusi F; Iovinelli D; Ahmed A; Trezza A; Spiga O; Sgaragli G; Valoti M
Eur J Pharmacol; 2021 May; 899():174030. PubMed ID: 33727059
[TBL] [Abstract][Full Text] [Related]
25. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
27. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
Stepanovic SZ; Potet F; Petersen CI; Smith JA; Meiler J; Balser JR; Kupershmidt S
J Physiol; 2009 Jun; 587(Pt 11):2555-66. PubMed ID: 19406877
[TBL] [Abstract][Full Text] [Related]
28. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
29. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
30. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.
Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA
Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465
[TBL] [Abstract][Full Text] [Related]
31. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
32. The Temperature Dependence of Kinetics Associated with Drug Block of hERG Channels Is Compound-Specific and an Important Factor for Proarrhythmic Risk Prediction.
Windley MJ; Lee W; Vandenberg JI; Hill AP
Mol Pharmacol; 2018 Jul; 94(1):760-769. PubMed ID: 29728448
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Orvos P; Kohajda Z; Szlovák J; Gazdag P; Árpádffy-Lovas T; Tóth D; Geramipour A; Tálosi L; Jost N; Varró A; Virág L
Toxicol Sci; 2019 Apr; 168(2):365-380. PubMed ID: 30561737
[TBL] [Abstract][Full Text] [Related]
34. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
35. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
[TBL] [Abstract][Full Text] [Related]
36. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
Nakaya H
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
[TBL] [Abstract][Full Text] [Related]
37. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
38. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
39. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
40. HERG K+ channel blockade by the novel antiviral drug sophocarpine.
Zhao XL; Qi ZP; Fang C; Chen MH; Lv YJ; Li BX; Yang BF
Biol Pharm Bull; 2008 Apr; 31(4):627-32. PubMed ID: 18379053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
